Detailed Information on Publication Record
2006
Serum HER-2/neu: a tumor marker for monitoring response to treatment of metastatic breast cancer with trastuzumab
GRELL, Peter, Katarína PETRÁKOVÁ, Marta ŠIMÍČKOVÁ, Marek SVOBODA, Miloslava NEKULOVÁ et. al.Basic information
Original name
Serum HER-2/neu: a tumor marker for monitoring response to treatment of metastatic breast cancer with trastuzumab
Name in Czech
Sérová HER-2/neu: nádorový marker pro monitoring odpovědi na léčbu trastuzumabem u metastatického karcinomu prsu
Authors
GRELL, Peter, Katarína PETRÁKOVÁ, Marta ŠIMÍČKOVÁ, Marek SVOBODA, Miloslava NEKULOVÁ, Ladislav PECEN, Rostislav VYZULA and Rudolf NENUTIL
Edition
1. vyd. Budapešť, 19th meeting of European Association For Cancer Research, p. 207-207, 1 pp. 2006
Publisher
European Association for Cancer Research
Other information
Language
English
Type of outcome
Stať ve sborníku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
Organization unit
Faculty of Medicine
Keywords in English
serum her2/neu;trastuzumab;breast cancer
Tags
International impact, Reviewed
Změněno: 25/1/2008 18:19, prof. MUDr. Marek Svoboda, Ph.D.
V originále
Introduction: HER-2/neu, the oncoprotein from growth factor receptor family, is overexpressed in primary tumor tissue in approximately 30% patients with breast cancer. Extracellular domain of this oncoprotein is released into the circulation and by recent studies it has prognostic and predictive signification similar to HER-2/neu in tissue. Material and Methods: We evaluated dynamics of serum HER-2/neu (S_HER2) changes during the course of trastuzumab-based therapy, by the specific antibody directed against the extracellular domain (ELISA, Oncogene Science, USA). We had opportunity to repeatedly tested S_HER2 in 69 patients with metastatic breast cancer undergoing treatment in years 200-2005 in our institute. Results: Patients without the response to treatment at the time of the first restaging (3 months), had significantly elevated S_HER2 levels, that generally do not drop below the discriminatory level. The patients with the best clinical response achieved (complete or partial response) are commonly S_HER2 negative after 3 months of the therapy, even if they were serum-positive at the beginning of the treatment. Serum CA15-3 and CEA levels do not show significant differences in this two groups of responders. Likewise in longitudinally monitoring over the time course of trastuzumab-based treatment the predictor of the therapy failure is mainly elevated S_HER2. Conclusion: Monitoring the concentrations of serum HER2 during the trastuzumab therapy appears to be a suitable therapy efficacy validation parameter both at the start and during long-term therapy application. Acknowledgements: The work was supported by grants from IGA MZCR: No. NR/8335-3 and No. NR/8270-3.
In Czech
Introduction: HER-2/neu, the oncoprotein from growth factor receptor family, is overexpressed in primary tumor tissue in approximately 30% patients with breast cancer. Extracellular domain of this oncoprotein is released into the circulation and by recent studies it has prognostic and predictive signification similar to HER-2/neu in tissue. Material and Methods: We evaluated dynamics of serum HER-2/neu (S_HER2) changes during the course of trastuzumab-based therapy, by the specific antibody directed against the extracellular domain (ELISA, Oncogene Science, USA). We had opportunity to repeatedly tested S_HER2 in 69 patients with metastatic breast cancer undergoing treatment in years 200-2005 in our institute. Results: Patients without the response to treatment at the time of the first restaging (3 months), had significantly elevated S_HER2 levels, that generally do not drop below the discriminatory level. The patients with the best clinical response achieved (complete or partial response) are commonly S_HER2 negative after 3 months of the therapy, even if they were serum-positive at the beginning of the treatment. Serum CA15-3 and CEA levels do not show significant differences in this two groups of responders. Likewise in longitudinally monitoring over the time course of trastuzumab-based treatment the predictor of the therapy failure is mainly elevated S_HER2. Conclusion: Monitoring the concentrations of serum HER2 during the trastuzumab therapy appears to be a suitable therapy efficacy validation parameter both at the start and during long-term therapy application. Acknowledgements: The work was supported by grants from IGA MZCR: No. NR/8335-3 and No. NR/8270-3.
Links
| NR8335, research and development project |
|